This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Genta Melanoma Drug Study Disappoints: BioBuzz

BERKELEY HEIGHTS, NJ ( TheStreet) -- The resurrection of Genta (GETA.OB) doesn't appear to have a happy ending.

The drug maker reported results Thursday from its latest phase III study of Genasense in melanoma and the data aren't encouraging.

Treatment with Genasense failed to demonstrate a statistically significant improvement in progression-free survival -- a co-primary endpoint of the study. Secondary endpoints of the study, including response rate and overall disease control rate, also failed to show a benefit favoring Genasense.

The only positive thing Genta had to say about the Genasense study was that the drug cleared a futility test for overall survival -- the other co-primary endpoint. But Genta said it was still too early to determine whether Genasense patients lived longer than those in the study's control arm.

Plans to seek Food and Drug Administration approval for Genasense in melanoma before the end of the year have now been put on hold given these results, said Genta CEO Ray Warrell.

Detailed data from the study will be presented on Nov. 15 at a meeting of cancer researchers in Boston.

In 2004, the FDA rejected Genta's application for Genasense in melanoma on the basis of a previous phase III study that also failed to demonstrate a survival benefit favoring the drug.

For this latest phase III study, Genta limited enrollment to a subset of melanoma patients with low levels of LDH, a blood enzyme, who appeared to live longer after treatment with Genasense during the first study. Conversely, patients with elevated levels of LDH were not helped at all by Genasense.

Safety Issues Delay Transcept Sleep Drug Approval

The FDA wants more safety data from Transcept Pharmaceuticals (TSPT) before approving the company's insomnia drug, the company said Thursday.

Transcept was seeking FDA approval for Intermezzo as a sleep aid for people who wake up in the middle of the night but can't fall back to sleep. The drug's active ingredient is a low dose of the popular sleeping pill Ambien formulated into a tablet that dissolves quickly in the mouth.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs